You are here: Industry Insights > cancer screening

News List

Blood test can detect more than 50 types of cancer pharmatimes
June 28, 2021
Researchers have developed a blood test able detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.
AnchorDx Jointly Publishes Clinical Research Paper: "Accurate Diagnosis of Pulmonary Nodules Using a Non-invasive DNA Methylation Test" prnasia
April 29, 2021
AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned thoracic experts from 14 top-tier hospitals in China, jointly published a clinical research paper entitled "Accurate Diagnosis of Pulmonary ...
BHU signs MoU with ICS for Ganga Godavari Cancer Screening Programme expresspharma
March 26, 2021
The Banaras Hindu University (BHU) and Indian Cancer Society (ICS) signed an MoU for conducting a cancer screening programme to facilitate early detection.
AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs prnasia
February 23, 2021
AnchorDx Medical Co., Ltd. announced the completion of a USD 40 million Series C financing. This round of financing was jointly led by OrbiMed, a world-renowned biomedicine and healthcare venture capital fund, and WuXi Huiying Investment ...
First Cancer Early Screening Company Listed on HKEX as New Horizon Health Debuts prnasia
February 18, 2021
Qiming's portfolio company New Horizon Health officially listed on the Main Board of Hong Kong, S.A.R., China Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company.
Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products prnasia
December 16, 2020
Singlera Genomics Inc. announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment.